John Charles Morris

John Charles Morris

Auto-generated profile, based on publicly available information

John Charles Morris

Department of Hematology-Oncology, Vontz Center for Molecular Studies, University of Cincinnati, 3125 Eden Ave, Cincinnati, OH 45267, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
IEIhab Eldessouki
Ihab Eldessouki
OGOla Gaber
Ola Gaber
TNTariq Namad
Tariq Namad
JWJiang Wang
Jiang Wang
JMJohn C. Morris
John C. Morris
NKNagla Abdel Karim
Nagla Abdel Karim
Large cell neuroendocrine cancer (LCNEC) of the lung exhibits morphological and immunohistochemical characteristics of both neuroendocrine and large cell carcinomas. No defined optimal therapy has been described for this subset of patients and the question of whether these patients should be treated with non-small cell lung cancer (NSCLC) treatment protocols, according to the National Comprehensive Cancer Network (NCCN) guidelines, or with small cell lung cancer (SCLC) due to histological and clinical similarities is still uncertain. We conducted a retrospective review of patients identified with diagnosis of LCNEC of the lung at the University of Cincinnati Cancer Center from the year 2002 to 2012 to determine which treatment approach resulted in improved outcomes in this rare category of disease. Patients who received chemotherapy whether NSCLC (group A) or SCLC (group B) protocols did not show significant changes in OS (P=0.911). Meanwhile, patients who underwent surgery (group C) had better OS compared to groups A and B (P= 0.027 and 0.024, respectively). This analysis reveals that outcomes for SCLC or NSCLC treatment strategies in LCNEC patients did not result in survival advantages and future research should be addressing it as a separate entity.

20 May 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RGRamaswamy Govindan
Ramaswamy Govindan
JMJohn Charles Morris
John Charles Morris
GRGabriela R. Rossi
Gabriela R. Rossi
NVNicholas N. Vahanian
Nicholas N. Vahanian
CLCharles J. Link
Charles J. Link
TPS8133 Background: Tergenpumatucel-L immunotherapy consists of allogeneic lung cancer cells that have been genetically modified to express the carbohydrate α(1,3)Gal, to which humans have an inherent pre-existing immunity. It is αGal that is primarily responsible for the hyperacute rejection of foreign tissue via this potent immune defense mechanism in humans. Tergenpumatucel-L leverages this mechanism to educate the immune system towards components of the patients’ own tumor cells. In a Phase 2 study of tergenpumatucel-L, patients with evidence of immune activation after therapy (11/18 patients with elevated IFN gamma via ELISPOT) had a median survival of 21.9 months. 16 of 28 patients went on to salvage therapy after progression and 9 of these 16 had objective responses (5PR, 4SD) to the post immunotherapy chemotherapy. This study is designed to further evaluate this potential chemo-sensitization effect of tergenpumatucel-L. Methods: This Phase 2B study is an open label, multi center randomized trial of single agent tergenpumatucel-L versus docetaxel. Eligible patients have pathologically confirmed NSCLC and may have previously undergone surgery, radiotherapy, and ≤ 2 prior chemotherapy regimens for this diagnosis. 240 patients will be randomized in a 2:1:1 manner to docetaxel (75mg/m2 q3 weeks x 4 doses) versus tergenpumatucel-L (300 million cell intradermally weekly for 11 weeks and then q2 months for 5 additional doses) versus tergenpumatucel-L (300 million cell q2 weeks for 6 doses and then monthly for 10 months). Patients will be monitored and at progression may stay on study and receive gemcitabine or premetrexed if randomized to the docetaxel arm or docetaxel or gemcitabine or premetrexed if randomized to one of the tergenpumatucel-L arms. Patients randomized to immunotherapy may continue to receive tergenpumatucel-L while on salvage chemo until all 16 planned doses are administered. This design with the patients staying on trial after progression is intended to capture and evaluate the possible chemo-sensitization seen in previous trials. Primary endpoint is overall survival. Clinical trial information: NCT01774578.